Cohance Lifesciences

1,066.50
-42.30
(-3.81%)
Market Cap
40,800.80 Cr
EPS
11.80
PE Ratio
101.39
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,119.00
52 Week Low
990.00
PB Ratio
16.00
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,699.80
#1 4,07,839.00
35.55
#1 49,887.20
12.06
#1 9,648
-18.99
45.69
6,631.50
1,76,045.50
80.38
8,184.00
0.89
1,600
23.05
64.51
1,476.90
1,19,276.70
22.62
26,520.70
14.17
4,155
30.28
46.70
3,161.10
1,06,986.00
55.56
10,785.70
11.59
1,656
10.91
42.78
1,248.20
1,04,156.70
#1 18.42
28,905.40
12.36
5,578
21.14
66.73
2,461.80
1,01,568.60
51.21
10,615.60
19.57
1,942
-10.91
48.11
924.75
93,051.50
19.92
19,831.50
13.82
3,831
-0.19
61.49
1,970.10
89,943.10
27.40
20,141.50
#1 19.94
1,936
#1 112.49
44.46
1,172.90
68,122.20
19.71
29,559.20
17.55
3,169
-0.50
47.14
30,350.00
64,491.60
45.58
6,097.20
10.80
1,201
27.83
49.13
Forecast
Actual
Growth Rate
Revenue Growth
-19.72 %
Net Income Growth
-26.99 %
Cash Flow Change
-21.59 %
ROE
-38.23 %
ROCE
-39.27 %
EBITDA Margin (Avg.)
-6.12 %

Quarterly Financial Results

Quarterly Financials
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
251
217
282
190
211
254
247
296
281
293
324
456
381
350
289
367
381
358
251
234
270
249
272
323
413
Expenses
129
95
147
99
108
126
140
138
166
149
179
206
207
188
179
207
198
181
133
154
180
151
154
189
329
EBITDA
122
122
135
91
103
128
107
158
116
144
144
251
174
162
111
160
183
178
118
80
90
98
118
133
84
Operating Profit %
49 %
52 %
46 %
45 %
41 %
47 %
41 %
50 %
36 %
43 %
40 %
48 %
43 %
45 %
36 %
41 %
47 %
48 %
42 %
30 %
29 %
35 %
40 %
38 %
18 %
Depreciation
6
6
6
6
7
7
8
9
8
9
9
11
10
12
12
12
12
13
12
13
17
13
17
20
27
Interest
2
4
4
8
7
3
3
2
2
2
1
1
2
2
0
1
5
1
1
2
2
2
2
3
6
Profit Before Tax
115
113
125
78
89
118
97
148
106
133
134
240
161
149
99
146
166
164
105
66
71
83
100
110
52
Tax
40
21
32
20
15
26
23
34
22
28
37
79
70
41
26
38
42
43
26
19
18
22
18
26
13
Net Profit
75
92
93
58
74
92
74
114
83
105
97
160
92
108
72
108
124
121
80
47
53
61
82
83
39
EPS in ₹
5.88
7.22
3.65
4.55
5.83
3.60
2.91
4.46
3.27
4.13
3.81
6.29
3.60
4.22
2.83
4.23
4.87
4.74
3.13
1.84
2.10
2.39
3.23
3.26
1.65

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
Total Assets
783
1,173
1,475
1,830
1,966
2,254
Fixed Assets
271
357
441
534
663
670
Current Assets
390
392
565
1,128
1,011
1,263
Capital Work in Progress
111
102
96
30
165
179
Investments
7
338
542
598
536
905
Other Assets
394
376
395
667
601
501
Total Liabilities
783
1,173
1,475
1,830
1,966
2,254
Current Liabilities
158
200
220
210
159
107
Non Current Liabilities
35
128
74
92
72
97
Total Equity
590
845
1,181
1,527
1,735
2,051
Reserve & Surplus
578
832
1,155
1,502
1,710
2,025
Share Capital
13
13
26
26
26
26

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
11
1
-5
37
20
-18
Investing Activities
-66
-414
-311
-136
-195
-362
Operating Activities
50
407
383
330
457
359
Financing Activities
26
7
-76
-157
-242
-14

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
May 2025
Promoter
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
50.10 %
50.10 %
50.10 %
50.10 %
50.10 %
66.41 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.01 %
10.14 %
9.54 %
9.80 %
10.70 %
10.84 %
11.05 %
7.38 %
DIIs
4.30 %
4.47 %
4.94 %
5.24 %
5.91 %
6.32 %
10.52 %
11.35 %
11.43 %
9.23 %
14.14 %
15.94 %
17.24 %
17.42 %
16.94 %
16.68 %
16.60 %
11.02 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
20.87 %
19.86 %
19.21 %
18.38 %
17.07 %
16.86 %
14.69 %
14.01 %
12.76 %
12.80 %
11.76 %
10.87 %
10.51 %
10.08 %
9.75 %
9.81 %
9.68 %
6.63 %
Others
14.84 %
15.68 %
15.86 %
16.38 %
17.02 %
16.82 %
14.78 %
14.64 %
15.81 %
17.97 %
4.08 %
3.04 %
12.59 %
12.59 %
12.50 %
12.56 %
12.55 %
8.55 %
No of Share Holders
75,207
92,534
96,532
86,447
85,725
86,088
82,577
79,412
72,885
72,167
73,715
70,052
68,932
65,777
69,337
84,210
86,325
88,658

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 5 2 5 6 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 1.01 0.32 1.06 0.89 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
28 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 May 2025 1,151.25 1,092.20
07 May 2025 CHANGE OF NAME Change Of Name
NA
07 May 2025 1,118.50 1,118.50
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 1,148.20 1,084.55
28 Nov 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
28 Nov 2024 1,266.90 1,259.05
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 1,197.40 1,250.60
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 848.75 990.80
15 Dec 2023 ANNUAL GENERAL MEETING Annual General Meeting
NA
15 Dec 2023 572.10 673.25
12 Sept 2022 DIVIDEND Dividend
₹ 5.00 /share
09 Sept 2022 492.90 477.85
12 Sept 2022 DIVIDEND Dividend
₹ 1.00 /share
09 Sept 2022 492.90 477.85
17 May 2022 DIVIDEND Dividend
₹ 1.00 /share
13 May 2022 580.15 507.45
17 May 2022 DIVIDEND Dividend
₹ 1.00 /share
13 May 2022 580.15 507.45
16 Feb 2022 DIVIDEND Dividend
₹ 2.00 /share
15 Feb 2022 558.50 522.45
16 Feb 2022 DIVIDEND Dividend
₹ 1.00 /share
15 Feb 2022 558.50 522.45
17 Aug 2021 DIVIDEND Dividend
₹ 1.00 /share
13 Aug 2021 514.80 559.70
18 Feb 2021 DIVIDEND Dividend
₹ 1.00 /share
17 Feb 2021 486.60 494.65
28 Sept 2020 BONUS Bonus
1:1
25 Sept 2020 383.55 383.70

Announcements

Compliances-Reg.24(A)-Annual Secretarial Compliance12 hours ago
Announcement under Regulation 30 (LODR)-Credit Rating18 hours ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome1 day ago
Financial Results For Period Ended March 31 20251 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Announcement under Regulation 30 (LODR)-Investor Presentation1 day ago
Board Meeting Outcome for Outcome Of Board Meeting1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
General Announcement4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Change In The Name And Trading SymbolMay 13, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 13, 2025
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011May 12, 2025
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.May 12, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.May 12, 2025
Announcement under Regulation 30 (LODR)-AllotmentMay 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 07, 2025
Announcement under Regulation 30 (LODR)-Change of Company NameMay 07, 2025
Intimation Of Effective Date Of Merger And Record DateApr 25, 2025
Update On MergerApr 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Cautionary Email Received From The Stock ExchangeApr 02, 2025
Cautionary Email Received From The Stock ExchangeApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 28, 2025
Update On MergerMar 27, 2025
Closure of Trading WindowMar 26, 2025
Board Meeting Intimation for To Consider And Approve The Financial Results For The Period Ended March 31 2025Mar 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Integrated Filing (Financial)Feb 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Board Meeting Outcome for Outcome Of The Board MeetingFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Closure of Trading WindowDec 27, 2024
Board Meeting Intimation for Approval Of Unaudited Financial ResultsDec 27, 2024

Technical Indicators

RSI(14)
Neutral
43.06
ATR(14)
Less Volatile
44.21
STOCH(9,6)
Overbought
84.21
STOCH RSI(14)
Neutral
76.70
MACD(12,26)
Bullish
2.94
ADX(14)
Weak Trend
22.06
UO(9)
Bearish
54.70
ROC(12)
Downtrend And Accelerating
-1.41
WillR(14)
Neutral
-40.70

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
0
0.00%
-2.89%
0.00%
Apr 2025
Samco Special Opportunities Fund Direct - Growth
0
0.00%
-2.30%
0.00%
Apr 2025
Union Small Cap Fund Direct-Growth
211051
1.63%
1.63%
1.63%
Apr 2025
Tata Flexi Cap Fund Direct - Growth
99280
0.36%
-1.42%
-1.92%
Apr 2025
Union Innovation & Opportunities Fund Direct - Growth
98494
1.27%
1.27%
1.27%
Apr 2025
Union Multicap Fund Direct - Growth
93311
1.00%
1.00%
1.00%
Apr 2025
HDFC MNC Fund Direct - Growth
45000
0.90%
0.90%
0.90%
Apr 2025
Union Midcap Fund Direct - Growth
90736
0.77%
0.77%
0.77%
Apr 2025
Union Children's Fund Direct - Growth
4212
0.74%
0.74%
0.74%
Apr 2025
Union Retirement Fund Direct - Growth
10105
0.72%
0.72%
0.72%
Apr 2025
Union Large & Midcap Fund Direct - Growth
50733
0.70%
0.70%
0.70%
Apr 2025
Union Flexi Cap Fund Direct-Growth
135000
0.69%
0.69%
0.69%
Apr 2025
Invesco India Flexi Cap Fund Direct - Growth
241290
1.00%
-0.57%
-0.83%
Apr 2025
Axis Momentum Fund Direct - Growth
62559
0.55%
0.55%
0.55%
Apr 2025
Invesco India Multicap Fund Direct-Growth
312317
0.94%
-0.47%
-0.67%
Apr 2025
Union ELSS Tax Saver Fund Direct-Growth
33233
0.43%
0.43%
0.43%
Apr 2025
JM Aggressive Hybrid Fund Direct-Growth
123248
1.75%
0.35%
0.19%
Apr 2025
Aditya Birla Sun Life MNC Fund Direct-Growth
0
0.00%
-0.32%
-0.44%
Apr 2025
DSP Healthcare Fund Direct - Growth
2489539
9.72%
0.23%
-0.53%
Apr 2025
DSP ELSS Tax Saver Fund Direct Plan-Growth
1910066
1.31%
-0.22%
-0.63%
Apr 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0
0.00%
-0.21%
-0.23%
Apr 2025
Edelweiss Multi Cap Fund Direct - Growth
222573
0.96%
0.20%
0.08%
Apr 2025
DSP Equity Opportunities Fund Direct Plan-Growth
1467138
1.16%
-0.19%
-0.58%
Apr 2025
ITI Pharma and Healthcare Fund Direct - Growth
100111
5.20%
-0.19%
-0.86%
Apr 2025
Invesco India Focused Fund Direct - Growth
1025381
3.16%
-0.18%
-0.75%
Apr 2025

About Cohance Lifesciences

Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Chairperson NameVIVEK SHARMA